Última Hora: "Sombras y méritos de las dos auditoras que analizarán a los bancos ... - Finanzas.com" Mon, 21 May 2012 17:40:25 GMT    "Wall Street amplía sus ganancias a media sesión - ABC.es" Mon, 21 May 2012 17:24:11 GMT    "Economía/Energía.- PSOE pide a Soria que aclare "de forma ... - elEconomista.es" Mon, 21 May 2012 17:57:14 GMT    "UE da "semanas" a Google para enmendar abusos por su dominio en ... - AFP" Mon, 21 May 2012 17:10:00 GMT    "Banesto nombra consejero delegado a Javier San Félix - El País.com (España)" Mon, 21 May 2012 17:34:00 GMT    "Bruselas insiste "en la necesidad de transparencia" a España - AFP" Mon, 21 May 2012 15:05:00 GMT    "Rajoy pide a la UE medidas inmediatas para recuperar la ... - Cinco Días" Mon, 21 May 2012 17:50:39 GMT    "Exdirectores de CAM rechazan su responsabilidad por la situación ... - Finanzas.com" Mon, 21 May 2012 17:11:08 GMT    "Preapertura alcista en Wall Street - Bolsamania.com" Mon, 21 May 2012 11:36:04 GMT    "Unicef: ´La pobreza tiene rostro de niño´ - Diario de Mallorca" Mon, 21 May 2012 17:21:04 GMT      Para más noticias, haga clic aquí.

Zona de Acceso
       
       
¿Recordarme? 

Busque más análisis técnicos aquí en nuestro foro: Análisis Técnicos
Nota: Los datos después de 2012-05-18 son temporales y pueden tener un valor de Apertura incorrecto hasta nueva actualización...
Cambiar para Gráfico Estático de Forest Laboratori

Subida de
+0,330 (+0,990%) Forest Laboratori - [Ticker: FRX]Gráfico Forest Laboratori  Noticias Forest Laboratori  Descargar Históricos de Metastock Forest Laboratori y Otros  Análisis Técnico Forest Laboratori  
Última Transacción33,530Hora de Cotización2012-05-21 - 18:51
Variación+0,330 (+0,990%)Rango 52 Semanas[28,470 - 40,520]
Máximo33,540Mínimo33,100
Volumen671.336Volumen Medio (3m)1.856.100
Demanda / OfertaN/AYieldN/A
Cierre Anterior33,200PER9,41%
Apertura33,210EPS3,57
Fecha Ex-DividendoN/AFecha DividendoN/A
Capitalización Bursátil9 Objetivo Estimado 1 Año36,030
Nota: Los datos pueden tener un retraso de algunos minutos.

 Noticias de Forest Laboratori [FRX]:   (ordenadas por relevancia)

Forest And Almirall To Present Aclidinium Bromide Clinical Data At The ...
TheStreet.com (press release)
By Business Wire 05/18/12 - 06:00 AM EDT Forest Laboratories, Inc. (NYSE: FRX) and Almirall, SA (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic ...

y más »

Forest and Almirall to Present Aclidinium Bromide Clinical Data at the ...
EON: Enhanced Online News (press release)
NEW YORK--(EON: Enhanced Online News)--Forest Laboratories, Inc. (NYSE: FRX) and Almirall, SA (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic ...
Data from Almirall, Forest Labs' aclidinium studies on COPD to be presented at ...News-Medical.net
FOREST LABORATORIES, INC. : Forest and Almirall to Present Aclidinium Bromide ...4-traders

los 4 artículos informativos »

Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive ...
MarketWatch (press release)
NEW YORK, May 14, 2012 (BUSINESS WIRE) -- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) today announced they will present linaclotide-related data in one oral presentation and 16 poster presentations during ...

y más »

Analyst Research on Teva Pharmaceutical Industries Limited and Forest ...
MarketWatch (press release)
... COMTEX) -- www.stockcall.com/ offers investors comprehensive research on the Drug Manufacturers - Other industry and has completed analytical research on Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) and Forest Laboratories Inc. (NYSE:FRX) .

y más »

Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results ...
MarketWatch (press release)
NEW YORK, May 04, 2012 (BUSINESS WIRE) -- Forest Laboratories, Inc. (NYSE:FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) Annual ...
Forest Labs. To Present Cariprazine, Levomilnacipran Results From Phase 3 TrialsNASDAQ

los 7 artículos informativos »

Zacks Reaffirms Neutral Rating on Forest Laboratories (FRX)
Junction Report
Forest Laboratories (NYSE: FRX)'s stock had its ?neutral? rating reiterated by Zacks in a note issued to investors on Monday. They currently have a $37.00 target price on the stock. Zacks' analyst wrote, ?Forest Labs is facing tough times with its lead ...

y más »

AstraZeneca Amarin-to-Forest Deal Seen on Lost Patents: Real M&A
BusinessWeek
(AMRN) (AMRN) to Forest Laboratories Inc. (FRX) (FRX) into takeover candidates. The UK's second-biggest drugmaker, which agreed this week to buy Ardea Biosciences Inc. (RDEA) (RDEA), is in talks with other companies about possible deals as it faces ...

y más »

Earnings Scorecard: Forest Labs
Zacks.com
Following the release of fourth quarter and fiscal 2012 results, most of the analysts covering Forest Laboratories (FRX - Analyst Report) have made downward revisions to their earnings estimates for fiscal 2013. The downward revision in estimates is ...

y más »

ThinkEquity Raises Price Target on Forest Laboratories (FRX)
Daily Political
Investment analysts at ThinkEquity lifted their target price on shares of Forest Laboratories (NYSE: FRX) to $40.00 in a note issued to investors on Tuesday. The firm currently has a ?buy? rating on the stock. Forest Laboratories traded down 0.69% on ...


Auriga Initiates Coverage on Forest Laboratories (FRX)
Daily Political
Investment analysts at Auriga began coverage on shares of Forest Laboratories (NYSE: FRX) in a note issued to investors on Thursday. The firm set a ?hold? rating and a $36.00 price target on the stock. Shares of Forest Laboratories traded up 0.78% ...


Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive ...
MarketWatch (press release)
NEW YORK & CASTRES, France, Apr 26, 2012 (BUSINESS WIRE) -- Forest Laboratories, Inc. (NYSE:FRX) and Pierre Fabre Medicament today announced additional positive results from a Phase III clinical trial of levomilnacipran, an investigational agent for ...

y más »

Yet Another Delay for Forest Labs - Analyst Blog
NASDAQ
Forest Laboratories ( FRX ) is facing another delay where the approval of one of its pipeline candidates is concerned. The company and its partner, Ironwood Pharmaceuticals, Inc. ( IRWD ) recently announced that the FDA has extended the review period ...

y más »

Healthcare Sectors Showed Positive Momentum- OREX, ARNA, VVUS, DVAX, TEVA ...
eStocksDaily
... Warner Chilcott Plc (NASDAQ:WCRX) moved up +0.23%, Amarin Corporation plc (ADR) (NASDAQ:AMRN) dropped -0.86%, Forest Laboratories, Inc. (NYSE:FRX) which increased +0.74% and Ardea Biosciences, Inc. (NASDAQ:RDEA) added +0.22%.

y más »

Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results ...
EON: Enhanced Online News (press release)
NEW YORK--(EON: Enhanced Online News)--Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) Annual ...


Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma ...
PR Newswire (press release)
CHICAGO, April 27, 2012 /PRNewswire/ -- Today, Zacks Equity Research discusses the Pharmaceuticals & Biotech Industry, including Eli Lilly (NYSE: LLY), Forest Labs (NYSE: FRX), ViroPharma (Nasdaq: VPHM), Novartis (NYSE: NVS) and United Therapeutics ...

y más »
Para más noticias de Forest Laboratori hacer clic aquí:
Noticias de Forest Laboratori 


Anchura de la Página:

 Imagen de Fondo:

Copyright@2009-2012 - BolsaES.com, todos los derechos reservados.
Foro de Bolsa Cotizaciones Noticias de Bolsa Chat de Bolsa Disclaimer Recursos para Webmasters